Ronald Gilley, MD
Psychiatry · Madisonville, KYNPI 1134462658
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,400 of the $3,512 with a category attached, or 68.3%. Lilly USA, LLC accounts for 68.3% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $2,604, more than ten times the $57 reported in 2019.
Across 57 payments — averaging $61.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Johnson & Johnson$455
- Lundbeck LLC$126
- Harmony Biosciences LLC$115
- Axsome Therapeutics, Inc.$76
- Sunovion Pharmaceuticals Inc.$70
- plus $270 from 8 others
What the payments were for
- Speaking & faculty fees$2,40068%
- Food & beverage$1,11232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1 | $2,400 |
| Johnson & Johnson(2 entities) | 25 | $455 |
| Lundbeck LLC | 7 | $126 |
| Harmony Biosciences LLC | 5 | $115 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| Sunovion Pharmaceuticals Inc. | 1 | $70 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$2,400
How this compares
$3,512 in reported general payments places this provider in the 80th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ramelteon | 16 | $3,674 |
| Aripiprazole | 18 | $1,349 |
| Armodafinil | 16 | $651 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $542 |
| Quetiapine Fumarate | 16 | $441 |
| Risperidone | 20 | $391 |
| Mirtazapine | 22 | $372 |
| Gabapentin | 21 | $168 |
| Hydroxyzine Pamoate | 20 | $56 |
| Ropinirole Hcl | 15 | $41 |
| Clonazepam | 15 | $35 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Madisonville
- Carmen PintoElizabethtown$1.7M
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Mark WrightLexington$637K
- Carol MillerFrankfort$462K
- Ali FarooquiLouisville$393K
- Steven CroleyLexington$151K
- Joseph HarrisonOwensboro$131K
- Stephanie HallLouisville$106K
- Jacob BishopLexington$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.